NanoClarithromycin

Nanomedicine for ClarithromycinFrom

www.nanomeda.comwww.nanosgroup.com

OPPORTUNITYAccording to Chinese Business Association reported that in 2007, with erythromycin-based macrolide antibiotics, total global sales of more than 90 million sales of clarithromycin in the global market has risen to 15 billion U.S. dollars, accounting for international macrolide antibiotics 18% of total sales, of which Abbott's patent-name drugs clarithromycin only half of the remaining shares are contributed by imitation. Because clarithromycin Preparation Popular hospital in the country, the domestic pharmaceutical manufacturers spotted the opportunity to develop the production of clarithromycin

Join us to take NanoClarithromycin to Clinic

What is Needed?

Emulsifier is an egg phosphatide. No Need of It!

Bio-available at all pH in all parts of digestive system in oral delivery formulations. pH independence needed.

Soybean oil, an egg phosphatide, oleic acid, hexanoic acid and glycerin elimination fro formulations. Zero Need Of It!

An effective, safe and most inexpensive nanomedicine for Clarithromycin. It is Needed!

To eliminate acids from formulation. Take It out !

A Genuine need is fulfilled

PROBLEMClarithromycin has relatively low solubility in water. Consequently, a tablet that comprises Clarithromycin and a water soluble filler such as sorbitol, without any disintegrant will dissolve too slowly to enable full release of the Clarithromycin after ingestion.

No Nanomedicine formulation developed so far.

Poor bio-availability

Toxicity

Problem Solved

Issues & NeedsIt has been found that erythromycin fat emulsions are locally non-irritative. The antibiotic clarithromycin, however, has a low solubility in fat emulsions even in the presence of oils, and will precipitate out of such emulsions. It has heretofore not been possible to solubilize clarithromycin so as to achieve stable injectable compositions at concentrations which are high enough for therapeutically effective pharmaceutical purposes.

There is a continuing need for stable injectable compositions of clarithromycin at therapeutically acceptable concentrations that do not cause severe pain at the injection site.

A genuine Project for investment

What is new?Present invention releases drug at all pH and faster than any existing formulation.

Invention for nanomedicine

Patented nanomedicine to prevent generic cliff

Most inexpensive manufacturing of nanomedicines.

Your manufacturing set-up remains same.

Why the market so big( $15Billion Market?)

Multiple uses

CompetitionFor Me-too

Brands

We stay away from Me-too

CUSTOMERS

https://docs.google.com/document/d/1DIxzmqnWzkB-t8tmAtL3LhxGucz7hoT0mYAcE4iqvY8/edit?usp=sharing

Click hyperlink to see our customers

Our customers for NanoClarithromycin

Join us to take this discovery to Clinic

What has been Established

SOP for pilot scale production

Analytical testing procedures for testing

Raw material

Lab. Testing

Funds ForTo move in cGMP manufacturing

Clinical trials

Marketing

Clarithromycin

Alexander Project USA 2000

PK/PD breakpoint based on current approved

dosing regimens

Susceptible breakpoint NCCLS PK/PDS. pneumoniae H. influenzae ALL

ORGANISMS

Clarithromycin 0.25 8 0.25

Solubility is a genuine needResolved by Meda Biotech llc.

Technology

1.

1. New molecule MR007 for nanoparticle2. MR007 provides synergistic3. Lowest manufacturing cost4. Strong patent5. No need of existing facility change6. No need to hire new staff

AvailableCapsules

Tablets Stable and 10X more potent

Syrup

Injectable

Nanomedicine for all

Contact

Mewa Singh, PhD609-902-7128mewasinghsandhu@hotmail.commynanoview@gmail.comwww.nanomeda.comwww.nanosgroup.comMeda Biotech,llc.Baton Rouge, LA 70803